CORAL GABLES, FL / ACCESSWIRE / January 24, 2019 / The marijuana stock market has largely benefitted from a massive influx of capital over the course of the last few years. It has become commonly understood that cannabis is somewhat of a miracle treatment for a variety of ailments. As of recent, the medical community has increasingly expressed their approval of cannabis as a means of treating everything from cancer to insomnia. With so much happening throughout the market in terms of innovation and investments, many cannabis companies in the space have invested in products and opportunities meant to attract investor attention. Given that the new year is less than one month old, its likely that opportunities may emerge from the nascent cannabis industry. GTEC Holdings Ltd (GTEC) (GGTTF), MariMed Inc (MRMD), Canopy Growth Corp (CGC) (WEED.TO), and Tilray Inc (TLRY) represent four companies committed to integrating cannabis as a means of improving the quality of life for consumers on a global scale.
GTEC Holdings Ltd (GTEC) (GGTTF) is a specialized craft cannabis company dedicated to cultivating premium quality cannabis in purpose-built indoor facilities. The company is vertically integrated across all major sectors of the Canadian cannabis industry and presently holds Cultivation, Extraction, and Analytical testing licenses.
GTEC Holdings Ltd (GTEC) (GGTTF) announced in early December 2018 that its wholly owned subsidiary, Alberta Craft Cannabis, had completed a major sale of cannabis products to CannMart Inc, a wholly owned subsidiary of Namaste Technologies Inc. In the months following the distribution deal, GTEC’s ultra-premium has risen to become the best-selling product presently available at CannMart.
MariMed Inc (MRMD) announced earlier this month that the Company had formed MariMed Hemp Inc, a wholly-owned subsidiary to be entirely focused on hemp-derived CBD products. MariMed Hemp will have a dedicated executive team, proprietary brand and product lines, and distribution and marketing relationships, all separate from MariMed’s core cannabis business.
Following the announcement, Robert Fireman, CEO of MariMed, said, “With the recent signing of the U.S. Farm Bill that declared hemp fully legal at the federal level, we believe the hemp CBD industry may grow even faster than the cannabis industry. Consumers and retailers alike seek the highest quality, trustworthy products. While many niche players may try to compete, the reality is that only a handful of suppliers can reliably deliver top-quality CBD products at scale that can serve the needs of major retailers.”
Canopy Growth Corp (CGC) (WEED) announced earlier this week that the Company had made significant progress in the UK and Poland cannabis markets where its medically-focused business Spectrum Cannabis continues to build a sophisticated, pan-European cannabis production and distribution network serving the needs of physicians and their patients throughout the continent.
In the United Kingdom the Company has formed Spectrum Biomedical UK, a new company focused on providing access to cannabis-based medicinal products to UK patients with the severe unmet clinical need. In addition to expanding its medicinal cannabis operations in the UK, Canopy Growth’s Toruń-based team, Spectrum Cannabis Polska, successfully completed its first import of medical cannabis after completing a rigorous regulatory approval process to have the product assessed and approved for sale.
Tilray Inc (TLRY) found itself in headlines earlier this week following their announcement that they had entered into a definitive agreement pursuant to which Tilray, through a wholly-owned subsidiary, will acquire all of the issued and outstanding securities of Natura Naturals Holdings Inc., the parent company of a licensed cultivator of cannabis.
Per the official details of the announcement, As a result of the acquisition, if completed, Tilray will obtain Natura’s 662,000 square-foot greenhouse cultivation facility, of which 155,000 square-feet are currently licensed, and all subsequent cannabis output from this facility. Under the terms of the definitive agreement and subject to certain customary adjustments, Tilray will deliver C$35 million at closing, comprised of C$15 million in cash and C$20 million in Tilray Class 2 common stock.
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GTEC Holdings Inc., Midam is being paid $63,333 per month from the company for a total of 12 months and has received ZERO shares of GTEC Holdings Inc. for a duration of beginning July 10, 2018 and ending July 10, 2019. We may buy or sell additional shares of (GTEC) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.For disclaimer information, click here.